Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387297869> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- W4387297869 endingPage "49" @default.
- W4387297869 startingPage "845" @default.
- W4387297869 abstract "Objective: To determine the real-world efficacy and safety of subcutaneous Tocilizumab in patients with rheumatoid arthritis.
 Study Design: Case series.
 Place and Duration of Study: Department of Rheumatology, National Hospital and Medical Centre, Lahore Pakistan, from Aug 2019 to Dec 2020.
 Methodology: In this study, 33 patients receiving subcutaneous Tocilizumab 162 mg every two weeks as monotherapy or with conventional synthetic disease modifying anti-rheumatic drugs were followed per standard study protocol. Increasing or decreasing the dosing interval was allowed according to disease activity at the discretion of the treating rheumatologist. The primary outcome was patients achieving Low Disease Activity as per Clinical Disease Activity Index (>2.8-10.0) and Disease Activity Score-28(>2.6-3.2). The secondary outcome was a clinically meaningful improvement in Disease Activity Score -28 (reduction of ≥1.2 units in Disease Activity Score-28 score). Adverse events were recorded at each follow-up visit.
 Results: Of the 33 patients, 25(75.8%) were biologics-naive, 9(27.2%) patients achieved the target of Low Disease Activity as per Clinical Disease Activity Index (2.9-10.0) and 8(24.2%) patients achieved Low Disease Activity as per Disease Activity Score-28(2.7-3.2). At six months, the proportion of patients achieving clinically meaningful improvement (decrease ≥1.2) in Disease Activity Score -28 was 13(54.2%). Overall, 14(42.4%) patients developed adverse events and 3(9.1%) patients discontinued Tocilizumab owing to adverse events.
 Conclusion: Tocilizumab has been seen to be an effective biologic in only one-third of patients, and it was tolerated in twothirds of the patients.Keywords: Conventional synthetic disease modifying anti-rheumatic drugs, Efficacy, Rheumatoid arthritis, Safety, Subcutaneous tocilizumab." @default.
- W4387297869 created "2023-10-04" @default.
- W4387297869 creator A5067213325 @default.
- W4387297869 creator A5068202681 @default.
- W4387297869 creator A5068321177 @default.
- W4387297869 creator A5069989694 @default.
- W4387297869 creator A5086862049 @default.
- W4387297869 creator A5091670483 @default.
- W4387297869 date "2023-06-22" @default.
- W4387297869 modified "2023-10-14" @default.
- W4387297869 title "Short-Term Efficacy and Safety of Subcutaneous Tocilizumab in Rheumatoid Arthritis Patients in Pakistan: A Real-World Experience" @default.
- W4387297869 doi "https://doi.org/10.51253/pafmj.v73i3.7266" @default.
- W4387297869 hasPublicationYear "2023" @default.
- W4387297869 type Work @default.
- W4387297869 citedByCount "0" @default.
- W4387297869 crossrefType "journal-article" @default.
- W4387297869 hasAuthorship W4387297869A5067213325 @default.
- W4387297869 hasAuthorship W4387297869A5068202681 @default.
- W4387297869 hasAuthorship W4387297869A5068321177 @default.
- W4387297869 hasAuthorship W4387297869A5069989694 @default.
- W4387297869 hasAuthorship W4387297869A5086862049 @default.
- W4387297869 hasAuthorship W4387297869A5091670483 @default.
- W4387297869 hasBestOaLocation W43872978691 @default.
- W4387297869 hasConcept C126322002 @default.
- W4387297869 hasConcept C197934379 @default.
- W4387297869 hasConcept C198451711 @default.
- W4387297869 hasConcept C2777178219 @default.
- W4387297869 hasConcept C2777575956 @default.
- W4387297869 hasConcept C71924100 @default.
- W4387297869 hasConceptScore W4387297869C126322002 @default.
- W4387297869 hasConceptScore W4387297869C197934379 @default.
- W4387297869 hasConceptScore W4387297869C198451711 @default.
- W4387297869 hasConceptScore W4387297869C2777178219 @default.
- W4387297869 hasConceptScore W4387297869C2777575956 @default.
- W4387297869 hasConceptScore W4387297869C71924100 @default.
- W4387297869 hasIssue "3" @default.
- W4387297869 hasLocation W43872978691 @default.
- W4387297869 hasOpenAccess W4387297869 @default.
- W4387297869 hasPrimaryLocation W43872978691 @default.
- W4387297869 hasRelatedWork W1838548883 @default.
- W4387297869 hasRelatedWork W1984273828 @default.
- W4387297869 hasRelatedWork W1987294331 @default.
- W4387297869 hasRelatedWork W2046399730 @default.
- W4387297869 hasRelatedWork W2123582592 @default.
- W4387297869 hasRelatedWork W2232273633 @default.
- W4387297869 hasRelatedWork W2736593664 @default.
- W4387297869 hasRelatedWork W2766107824 @default.
- W4387297869 hasRelatedWork W2783466784 @default.
- W4387297869 hasRelatedWork W4239841759 @default.
- W4387297869 hasVolume "73" @default.
- W4387297869 isParatext "false" @default.
- W4387297869 isRetracted "false" @default.
- W4387297869 workType "article" @default.